Mr. Bill Mitoulas reports

MEDX ANNOUNCES APPOINTMENT OF STEPHEN LOCKYER AS CEO

Stephen Lockyer has been appointed as chief executive officer, effective immediately, in place of Naman Damaghlatrous, who has resigned both as an officer and director of MedX Health Corp.

"Stephen, who became a major investor in the company in recent months and who joined the board in April, 2023, brings extensive knowledge and years of financial management and entrepreneurial experience, and was instrumental in the introduction of the project with PharmaChoice, which has just been launched in Canada," said Ken McKay, chairman of the MedX board of directors.

Mr. Lockyer stated, "I am very enthusiastic for the future of MedX and I look forward to building on the opportunities that are now opening up."

About MedX Health Corp.

MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy on DermSecure telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products Siametrics, Simsys and MoleMate, which MedX manufactures in its ISO 13485-certified facility. Siametrics, Simsys and MoleMate include hand-held devices that use patented technology utilizing light and its remittance to view up to two millimetres beneath suspicious moles and lesions in a pain-free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration, and Conformite Europeenne for use in Canada, the United States, Australia, New Zealand, the European Union, Brazil and Turkey.